- Sonrai Security announced a $50M Series C funding round. - The round was led by ISTARI, a global cybersecurity platform dedicated to helping clients build cyber resilience, with participation from existing investors Polaris Partners, Menlo Ventures, TenEleven Ventures and New Brunswick Innovation Fund. - The Series C round brings the total capital raised by Sonrai to $88 million. - Sonrai plans to use new funding to accelerate research and development and expand sales and marketing globally for the company’s industry-leading cloud security platform. - Public cloud complexity for global enterprises is exploding as microservices, workloads and associated 'non-people’ identities proliferate rapidly. - Sonrai has identified 17,000 unique permissions settings across AWS, Azure and GCP cloud platforms with approximately 20 new permissions added daily.

– Nomad Health, the leading digital marketplace for temporary healthcare jobs, announced the completion of $63m in new equity and debt financing.
– Adams Street Partners led, and all existing investors participated, including Icon Ventures, Polaris Partners, RRE Ventures, .406 Ventures, First Round Capital, and Silicon Valley Bank.
– With this financing, the business has raised over $100m since the company’s inception in 2015.
– The funding will be used to support Nomad Health’s explosive growth, allowing the company to double down on efforts to hire, invest in the technology platform, and grow its national footprint.
– As the demands on the healthcare system have reached historic levels during the COVID-19 pandemic, the need and urgency for temporary healthcare staffing solutions has substantially increased.

– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, announced the closing of a $50m Series B financing.
– The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.
– Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.

– ByHeart is a NYC-based baby nutrition company.
– Company raised $90M in series B funding.
– The round was led by D1 Capital Partners with participation from OCV Partners, Polaris Partners, Bellco Capital, Two River and Red Sea Ventures – all of whom also invested in ByHeart’s Series A – as well as new investment from AF Ventures, and Gaingels.
– The new capital will be used to launch the company’s first formula, as well as to advance its innovation pipeline of mom and baby products.

– FloQast, an accounting collaboration, automation, and close-management platform, has raised $110 million in a series D round of funding at a $1.2 billion valuation.
– The round was led by Meritech Capital, with participation from Insight Partners, Redpoint Ventures, Sapphire Ventures, Coupa Ventures, Polaris Partners, and Norwest Venture Partners.
– Financial close management is the business process of checking and adjusting account balances at the end of each month or other predefined period to publish compliant financial reports for regulators, managers, shareholders, or any other stakeholder that needs to know a company’s current financial position.

– OM1, a Boston MA-based health technology company, raised $85M in funding.
– The round was led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital with participation from General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest.
– The new investment will be used to expand its real-world data cloud, clinical registries, and AI platform for real-world evidence and personalized medicine.

– Muna Therapeutics from Copenhagen develops small molecule programs focused on repairing neuronal dysfunction, resolving neuroinflammation and restoring neuroprotection and resilience to disease.
– The company raised $73m in Series A funding.
– The round was led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB.
– The company intends to use the funds to advance its programs to IND applications.

– Wealthy, a New York-based digital care concierge platform that partners with employers to find care for employees and their families, raised $35M in Series B funding.
– The round was led by Rethink Impact with participation from Hearst, Polaris Partners, and Eldridge.
– The company intends to use the funds to grow and enhance its smart recommendations engine, advance its predictive support pathways, and launch an online community where families can exchange tips and ideas with other caregivers and gain insights from experts.

– Wellthy, a digital care concierge platform that partners with employers to find affordable, high-quality care for employees and their families, announced that it has raised an additional $35m in Series B funding to support the company’s international expansion, product development, and continued growth.
– Wellthy’s oversubscribed round was led by Rethink Impact, the largest venture capital fund in the U.S. committed to backing female leaders using technology to tackle the world’s greatest challenges.
– Rethink Impact was joined by additional strategic partners and existing investors Hearst, Polaris Partners, and Eldridge.
– The growth capital will fund Wellthy’s international expansion, including recent launches in Canada and the U.K. in response to growing demand from multinational businesses.

– Lyndra Therapeutics from Watertown, MA develops a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options.
– The company closed a $60.5m Series C financing round.
– The round was led by new investor, AIG Investments, an affiliate of American International Group with participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Ventures and the Catalytic Impact Foundation with ImpactAssets, and existing investors Polaris Partners, Invus, Quark Venture, Mass General Brigham Ventures, HOPU Investments, and Gilead Sciences, Inc.

– CAMP4 Therapeutics announced that it has raised $45m to propel the next phase of its scientific strategy, significantly expand its platform and advance multiple preclinical RNA therapies into human testing.
– CAMP4 is combining its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that enable tunable upregulation of gene expression to treat disease.
– CAMP4’s approach uniquely targets a new class of RNA known as regulatory RNAs (“regRNAs”) that control the expression of proteins, making this approach applicable to any genetic disease whereby a small increase in gene output can lead to meaningful therapeutic outcomes.
– 5AM Ventures and Northpond Ventures led the financing alongside existing investors Andreessen Horowitz, Polaris Partners and The Kraft Group.

– Kojin Therapeutics Inc. launched with a $60m Series A led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital, with participation from Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
– The company plans to use the proceeds of the Series A to accelerate its drug discovery platform based on its groundbreaking approach to cell state and ferroptosis biology and advance a robust pipeline of therapeutics, with an initial focus on oncology.

– Thirty Madison, a New York-based healthcare company that focuses on people with chronic conditions, raised $140M in Series C funding.
– The round was led by new investor HealthQuest Capital with participation from Mousse Partners and Bracket Capital and existing investors Polaris Partners, Johnson & Johnson Innovation – JJDC, Inc., Northzone, Greycroft, and others.
– The company intends to use the funds to expand access to its care model for people who suffer from chronic conditions and enhance the capabilities of its proprietary platform.

– August Bioservices, a Nashville, Tenn.-based contract development and manufacturing organization (CDMO) providing drug discovery, development, and pharmaceutical manufacturing services, closed a $23.6m Series A extension.
– The round was led by Polaris Partners, who joined existing investor Oak HC/FT. As part of the financing, Brian Chee, Managing Partner of Polaris Partners, joined the August Bioservices’ board as a Director. Darren Carroll of Polaris Partners joined the board as an observer.
– The company intends to use the funds to expand its manufacturing capacity and capabilities to advance the technology platforms needed to support production of sterile injectable medications.

– Engine Biosciences announced the successful completion of an oversubscribed $43m Series A funding round.
– Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
– This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore.
– Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
– Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.

– PureTech Health plc, a clinical-stage biotherapeutics company, announced that its Founded Entity, Akili Interactive, has secured $160 million of combined equity and debt financing.
– The financing included a $110 million Series D equity financing round led by Neuberger Berman Funds and joined by new investors Polaris Partners, Mirae Assets, Shionogi & Co., Ltd., New Leaf Venture Partners, Dave Baszucki (Founder and CEO of Roblox Corporation), QUAD Investment Management, and Ladera Venture Partners and a credit facility for up to $50 million with Silicon Valley Bank.

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.

– Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336m Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor.
– Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds also participated in the financing.

– Tausight raised $20m in Series A funding to help solve one of the most challenging responsibilities of healthcare CIOs and CISOs: ensuring the confidentiality, integrity, and availability of patients’ protected health information (PHI).
– The funding round was co-led by existing investors Polaris Partners and Flare Capital Partners, alongside new investor .406 Ventures.
– Tausight will help healthcare provider CIOs, CISOs, and their IT organizations better secure clinical workflows when clinicians access and use PHI.
– The company will use the funding to expand its go-to-market team and further build out its healthcare-specific solution for exposing the hidden vulnerabilities in clinical workflows that can put patient data at risk.

– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.

– eGenesis from Cambridge, Mass. develops human-compatible organs, tissues, and cells.
– The company raised $125m in Series C funding.
– Backers included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, and Osage University Partners and existing investors Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, and Alta Partners.

– SpineZone is a San Diego, CA-based provider of non-operative, personalized treatment for musculoskeletal conditions.
– The company closed a Series A funding round of $12m.
– The round was led by Polaris Partners and Providence Ventures, with participation from Martin Ventures.
– SpineZone intends to use the funds to enter into new markets and strategic partnerships with health systems, health plans, employers, and other organizations, along with expanding its clinic presence.

– Armorblox announced that it raised $30m in Series B venture capital funding.
– The funding was led by Next47 with participation from Polaris Partners and Unusual Ventures, as well as General Catalyst and other early investors.
– Armorblox is on a mission to restore and uphold trust in email communications by stopping targeted, socially engineered attacks from compromising people and data.
– The funding comes amidst fast-paced customer growth during 2020, accelerated further by the widespread shift to remote work and a growing discontent with the complexity and ineffectiveness of traditional email security controls.
– Already protecting over 9,000 organizations, Armorblox is using the new funding to expand its go-to-market, engineering, and data science teams and further cement its position as a next-generation email security provider that is centered around delivering customer value.

– Seraxis announced the closing of a $40M Series C financing round.
– The round was led by Eli Lilly and Company with participation from Frazier Healthcare Partners, Polaris Ventures, JDRF T1D Fund, and other investors.
– Seraxis is a privately held biotechnology company with operations located in the BioHealth Capital Region, Maryland.
– Seraxis proprietary transplant ready islets and device were developed in house.
– Seraxis is advancing its cell therapy/device combination, SR-01 to the clinic.